Intensive Care Medicine

, Volume 24, Issue 8, pp 756–768 | Cite as

Applications of thrombolytic therapy

  • N. Curzen
  • R. Haque
  • A. Timmis
Review

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gersch BJ, Chesebro JH, Clements IP (1991) Acute myocardial infarction: management and complications. In: Giuliani ER, et al. (eds) Cardiology: fundamentals and practice. Mosby, St. Louis, pp 1362–1452Google Scholar
  2. 2.
    DeBono D (1989) Problems in thrombolysis. In: Julian DG, et al. (eds) Thrombolysis in Cardiovascular Disease. Dekker, New York, pp 279–292Google Scholar
  3. 3.
    Topol EJ, Morris DC, Smalling RW, et al. (1987) A multicenter, randomised, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol 9:1205–1213PubMedGoogle Scholar
  4. 4.
    Loscalzo J (1990) Molecular biological modification of plasminogen activators, an artful science. Circulation 82: 1062–1063PubMedGoogle Scholar
  5. 5.
    Smalling RW (1997) Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 18 (Suppl F): Fll-16Google Scholar
  6. 6.
    Davies MJ (1989) The pathology of ischaemic heart disease. In: Julian DG, et al. (eds) Diseases of the heart. Saunders, London, pp 1035–1066Google Scholar
  7. 7.
    Lie JT (1991) Pathology of coronary artery disease. In: Giuliani ER, et al. (eds) Cardiology: fundamentals and practice. Mosby, St. Louis, pp 1211–1231Google Scholar
  8. 8.
    Haverkate F, Thompson SG, Pyke SDM, et al. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349: 462–466PubMedCrossRefGoogle Scholar
  9. 9.
    Ambrose JA, Fuster V (1998) The risk of coronary occlusion is not proportional to the prior severity of coronary stenoses. Heart 79: 3–4PubMedGoogle Scholar
  10. 10.
    Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977) The wave front phenomenon of ischemic cell death: myocardial infarct size versus duration of coronary occlusion in dogs. Circulation 56: 786–794PubMedGoogle Scholar
  11. 11.
    Mathey DG, Sheehan FH, Schofer J, et al. (1985) Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 6: 518–525PubMedGoogle Scholar
  12. 12.
    Fine DG, Weiss AT, Sapoznikov D, et al. (1986) Importance of early initiation of streptokinase therapy for acute myocardial infarction. Am J Cardiol 58: 411–417PubMedCrossRefGoogle Scholar
  13. 13.
    The TIMI Study Group (1985) The thrombolysis in acute myocardial infarction (TIMI) trial: Phase 1 findings. N Engl J Med 312: 932–936Google Scholar
  14. 14.
    Verstraete M, Bernard R, Bory M, et al. (1985) Randomised trial of intravenous rt-PA versus intravenous streptokinase in acute myocardial infarction. Lancet 1 (8433): 842–847PubMedCrossRefGoogle Scholar
  15. 15.
    Gruppo Italiano per lo Studio della Streptochinasi nell’Tnfarcto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 (8478): 397–402Google Scholar
  16. 16.
    ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2: 349–360Google Scholar
  17. 17.
    Wilcox RG, Von der Lippe G, Olsson CG, et al. (1988) Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2: 525–530PubMedCrossRefGoogle Scholar
  18. 18.
    GISSI-2 (1990) A factorial randomized trial of alteplase versus STREPTOKINASE and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336: 65–71Google Scholar
  19. 19.
    The International Study Group (1990) In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336: 71–75CrossRefGoogle Scholar
  20. 20.
    ISIS-3 (1992) A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339: 753–770CrossRefGoogle Scholar
  21. 21.
    Califf RM (1997) The GUSTO trial and the open artery hypothesis. Eur Heart J 18 (Suppl F): F2–10PubMedGoogle Scholar
  22. 22.
    Neuhaus KL, et al. (1989) Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14 (6): 1566–1569PubMedCrossRefGoogle Scholar
  23. 23.
    The Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO 1) investigators (1993) An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682CrossRefGoogle Scholar
  24. 24.
    Smalling RW, Bode C, Kalbfleisch J, et al. (1995) More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91: 2725–2732PubMedGoogle Scholar
  25. 25.
    Bode C, Smalling RW, Berg G, et al. (1996) Randomised comparison of coronary thrombolysis achieved with double bolus reteplase and front-loaded accelerated alteplase in patients with acute myocardial infarction. Circulation 94: 891–898PubMedGoogle Scholar
  26. 26.
    International Joint Efficacy Comparison of Thrombolytics (1995) Randomised, double blind comparison of reteplase double bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 346: 329–336CrossRefGoogle Scholar
  27. 27.
    Kanasama K, Watanabe I, Cercek B, Yano J, Fishbein MC, Ganz W (1989) Selective decrease in lysis of old thrombi after rapid administration of tissue-type plasminogen activator. J Am Coll Cardiol 14:1359–64CrossRefGoogle Scholar
  28. 28.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 343: 311–322Google Scholar
  29. 29.
    Collins R, Peto R, Baigent C, Sleight P (1997) Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336: 847–860PubMedCrossRefGoogle Scholar
  30. 30.
    The European Myocardial Infarction Project (EMIP) group (1993) Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329: 383–389CrossRefGoogle Scholar
  31. 31.
    Grampian Region Early Anistreplase Trial (GREAT) group (1992) Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. BMJ 305: 548–553CrossRefGoogle Scholar
  32. 32.
    Weaver WD, Cerqueira M, Hallstrom AP, et al. for the Myocardial Infarction Triage and Intervention (MITI) Project Group (1993) Pre-hospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 270: 1211–1216PubMedCrossRefGoogle Scholar
  33. 33.
    Fox KAA (1995) The thrombolysis trials and clinical practice. In: Ball SG (ed) Myocardial infarction: from trials to practice. Wrightson Biomedical Publishing, Petersfield, UK, pp 99–112Google Scholar
  34. 34.
    Honan MB, Harrell FE, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA (1990) Cardiac rupture mortality and the timing of thrombolytic therapy: a meta analysis. J Am Coll Cardiol 16: 359–365PubMedGoogle Scholar
  35. 35.
    The Late Assessment of Thrombolytic Efficacy (LATE) Steering Committee (1993) Late assessment of thrombolytic efficacy with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 342: 759–766CrossRefGoogle Scholar
  36. 36.
    Zahger D, Gotsman MS (1995) Thrombolysis in the era of the randomised trials. Curr Opinion Cardiol 10: 372–380Google Scholar
  37. 37.
    Brouwer MA, Bohncke JR, Veen G, Meijer A, Van Eenige MJ, Verheugt FW (1995) Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 26:1440–1444PubMedCrossRefGoogle Scholar
  38. 38.
    Ohman EM, Califf RM, Topoi EJ, Candela R, Abbotsmith C, Ellis S, Sigmon KN, Kerriakes D and the TAMI Study Group (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82: 781–791PubMedGoogle Scholar
  39. 39.
    Gore JM, Granger CB, Simoons ML, et al. (1995) Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation 92: 2811–2818PubMedGoogle Scholar
  40. 40.
    The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology (1996) Acute myocardial infarction: prehospital and in-hospital management. Eur Heart J 17: 43–63Google Scholar
  41. 41.
    Boersma E, Simoons ML (1997) Reperfusion strategies in acute myocardial infarction. Eur Heart J 18:1703–1711PubMedGoogle Scholar
  42. 42.
    The GUSTO angiographic investigators (1993) The effects of tPA, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRefGoogle Scholar
  43. 43.
    Neuhaus KL, Essen R von, Tebbe U, et al. (1994) Safety observations from the pilot phase of the randomised Hirudin for improvement of the thrombolysis (HIT-3) study. A study of the ALKK. Circulation 90: 1638–1642Google Scholar
  44. 44.
    Cannon CP, McCabe CH, Henry TD, et al. for the TIMI-5 Investigators (1994) A pilot trial of recombinant desulfato-hirudin compared to heparin in conjunction with tPA and aspirin for acute myocardial infarction. Results of the TIMI-5 trial. J Am Coll Cardiol 23: 993–1003PubMedCrossRefGoogle Scholar
  45. 45.
    Antman E A for the TIMI-9a Investigators (1994) Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9a trial. Circulation 90:1624–1630Google Scholar
  46. 46.
    The GUSTO IIA Investigators (1994) Randomised trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90: 1631–1637Google Scholar
  47. 47.
    The GUSTO-IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782CrossRefGoogle Scholar
  48. 48.
    Antman EM (1996) Hirudin in acute myocardial infarction. TIMI-9b Trial. Circulation 94: 911–921PubMedGoogle Scholar
  49. 49.
    The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330: 956–961CrossRefGoogle Scholar
  50. 50.
    The CAPTURE Investigators (1997) Randomised placebo controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina. Lancet 349:1429–1435CrossRefGoogle Scholar
  51. 51.
    The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl J Med 336:1689–1696CrossRefGoogle Scholar
  52. 52.
    Kothari R, Pancioli A, Brott T, Broderick J (1996) Thrombolytic therapy for cerebral infarction. Acad Emerg Med 3: 881–892PubMedCrossRefGoogle Scholar
  53. 53.
    Herndon RM, Meyer JS, Johnson JF (1960) Fibrinolysin therapy in thrombotic diseases of the nervous system. J Mich St Med Soc 59:1684–1692Google Scholar
  54. 54.
    Meyer JS, Gilroy J, Barnhart MI, Johnson JF (1963) Therapeutic thrombolysis in cerebral thromboembolism. Neurology 13: 927–937PubMedGoogle Scholar
  55. 55.
    Clarke RL, Clifton E (1960) The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Am J Cardiol 6: 546–551PubMedCrossRefGoogle Scholar
  56. 56.
    Fletcher AP, Alkjersig N, Lewis M, et al. (1976) A pilot study of urokinase therapy in cerebral infarction. Stroke 7: 135–142PubMedGoogle Scholar
  57. 57.
    Sundt TM, Grant WC, Garcia JH (1969) Restoration of middle cerebral artery flow in experimental infarction. J Neurosurg 80: 336–339Google Scholar
  58. 58.
    Crosswell RM, Olsson Y, Klatzo I, Omaya A (1970) Temporary occlusion of the middle cerebral artery in the monkey: clinical and pathological observations. Stroke 1: 439–448Google Scholar
  59. 59.
    Jones TH, Morawetx RB, Crowell RM, et al. (1981) Threshold of focal ischaemia in awake monkey. J Neurosurg 54: 773–782PubMedGoogle Scholar
  60. 60.
    Zivin JA, Fisher M, DeGirolami U, Hemmenway CC, Stashak JA (1985) Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 330:1289–1292CrossRefGoogle Scholar
  61. 61.
    Del Zopo GJ, Copeland BR, Waltz TA, Zyroff J, Plow EF, Harker LA (1986) The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 17: 638–643Google Scholar
  62. 62.
    Hirschberg M, Hoffenberth B (1997) Thrombolytic therapy with urokinase and pro-urokinase in a canine model of acute stroke. Neurology 37 (Suppl 1): 132Google Scholar
  63. 63.
    DeLey G, Weyne J, DeMeester G, et al. (1988) Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. J Cereb Blood Flow Metab 8: 539–545Google Scholar
  64. 64.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 333:1581–1587CrossRefGoogle Scholar
  65. 65.
    The Multicentre Acute Stroke Trial-Europe Study Group (1996) Thrombolytic therapy with streptokinase in acute myocardial ischemic stroke. N Engl J Med 335: 145–150CrossRefGoogle Scholar
  66. 66.
    Pilger E (1996) Thrombolytic therapy in acute lower limb ischemia. Semin Thromb Hemost 22: 61–67PubMedCrossRefGoogle Scholar
  67. 67.
    Abbott WM, Maloney RD, McCabe CC (1982) Arterial embolism: a 44 year perspective. Am J Surg 143: 460–464PubMedCrossRefGoogle Scholar
  68. 68.
    Yeager RA, Moneto GL, Taylor LM, Porter J (1992) Surgical management of severe acute lower extremity ischemia. J Vase Surg 15: 385–391CrossRefGoogle Scholar
  69. 69.
    The STILE Investigators (1994) Results of a prospective trial of surgery versus thrombolysis for the ischemic lower extremity: the STILE trial. Ann Surg 220: 251–268CrossRefGoogle Scholar
  70. 70.
    Ouriel K, Shortell CK, DeWeese JA, et al. (1994) A comparison of thrombolytic therapy with operative revascularisation in the initial treatment of acute peripheral arterial ischaemia. J Vase Surg 19:1021–1030Google Scholar
  71. 71.
    Dotter CT, Rosch J, Seamen AJ (1974) Selective clot lysis with low dose streptokinase. Radiology 111: 31–37PubMedGoogle Scholar
  72. 72.
    Braithwaite BD, Quinones-Baldrich WJ (1996) Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. World J Surg 20: 649–654PubMedCrossRefGoogle Scholar
  73. 73.
    Berridge DC, Gregson RH, Hopkinson BR, Makin GS (1991) Randomised trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg 78: 995–998Google Scholar
  74. 74.
    Meyerovitz MF, Goldhaber SZ, Reagan K, et al. (1990) Recombinant tissue-type plasminogen activator versus urokinase in peripheral and graft occlusions: a randomised trial. Radiology 175: 75–78PubMedGoogle Scholar
  75. 75.
    Graor RA, Risius B (1987) Thrombolysis with recombinant human-type plasminogen activator in patients with peripheral artery and bypass graft thrombosis. In: Sobel BE, et al. (eds) Tissue plasminogen activator in thrombolytic therapy. Dekker, New York, pp 171–204Google Scholar
  76. 76.
    McNamara TO (1995) Thrombolysis as the initial treatment for acute lower limb ischaemia. In: Camerota AJ (ed) Thrombolytic therapy for peripheral vascular disease. Lippincott, Philadelphia, pp 253–268Google Scholar
  77. 77.
    Ryu JH, Rooke TW, Rosenow EC (1991) Venous thromboembolism. In: Giuliani ER, et al. (eds) Cardiology: fundamentals and practice. Mosby, St. Louis, pp 2069–2086Google Scholar
  78. 78.
    Mclntyre KM, Sasahara AA (1973) Determinants of cardiovascular responses to pulmonary embolism. In: Moser KM, Stein M (eds) Pulmonary thromboembolism. Year Book Publishers, Chicago, pp 178–186Google Scholar
  79. 79.
    Tapson VF (1997) Pulmonary embolism — new diagnostic approaches. N Engl J Med 336:1449–1451PubMedCrossRefGoogle Scholar
  80. 80.
    Simonneau G, Sors H, Charbonnier B, et al. (1997) A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 337: 663–669PubMedCrossRefGoogle Scholar
  81. 81.
    Jezek V (1997) Thrombolysis in acute pulmonary embolism: to whom, how much and how? Eur Heart J 18:1045PubMedGoogle Scholar
  82. 82.
    Browse NL, James DC (1964) Streptokinase and pulmonary embolism. Lancet 2:1039–1043PubMedCrossRefGoogle Scholar
  83. 83.
    Tibbutt DA, Davies JA, Anderson JA, et al. (1974) Comparison by controlled clinical trial of streptokinase and heparin in the treatment of life-threatening pulmonary embolism. BMJ 1: 343–347PubMedCrossRefGoogle Scholar
  84. 84.
    Ly B, Arnesen H, Eie H, Hol R (1978) A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 203: 465–470PubMedGoogle Scholar
  85. 85.
    Jerjes-Sanchez C, Ramirez-Rivera A, Garcia-Molinedo M, et al. (1995) Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomised controlled trial. J Thromb Thrombolysis 2: 67–69Google Scholar
  86. 86.
    Meneveau N, Schiele F, Vuillemenot A, et al. (1997) Streptokinase versus alteplase in massive pulmonary embolism: a randomised trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 18: 1141–1148PubMedGoogle Scholar
  87. 87.
    More RS, Chauhan A (1996) Pulmonary embolism — the role of thrombolytic therapy in its management. Postgrad Med J 72:157–161PubMedCrossRefGoogle Scholar
  88. 88.
    Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ (1997) Thrombolytic therapy for pulmonary embolism. Frequency of intracranial haemorrhage and associated ristreptokinase factors. Chest 111: 1241–1245PubMedCrossRefGoogle Scholar
  89. 89.
    Doerge HC, Schoendube FA, Loeser H, Walter M, Messmer BJ (1996) Pulmonary embolectomy: review of a 15-year experience and role in the age of thrombolytic therapy. Eur J Cardiothorac Surg 10: 952–957PubMedCrossRefGoogle Scholar
  90. 90.
    Fava M, Loyola S, Flores P, Huete I (1997) Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. J Vase Interv Radiol 8: 261–266CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • N. Curzen
    • 1
  • R. Haque
    • 1
  • A. Timmis
    • 1
  1. 1.Department of CardiologyLondon Chest HospitalLondonUK

Personalised recommendations